Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1979 2
1985 1
1986 1
1995 1
1996 2
1997 1
1998 1
1999 2
2001 1
2002 1
2004 2
2005 6
2006 2
2007 4
2008 3
2009 5
2010 9
2011 8
2012 7
2013 3
2014 9
2015 7
2016 4
2017 6
2018 1
2019 1
2020 3
2021 7
2022 5
2023 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Oncology and complications.
Giordano G, Kyriazi E, Mavridis C, Persico F, Fragkoulis C, Gatto P, Georgiadis G, Giagourta I, Glykas I, Hurle R, Lazzeri M, Lughezzani G, Magnano San Lio V, Mamoulakis C, Meo D, Papadaki HA, Piaditis G, Pontikoglou C, Stathouros G. Giordano G, et al. Among authors: piaditis g. Arch Ital Urol Androl. 2021 Mar 19;93(1):71-76. doi: 10.4081/aiua.2021.1.71. Arch Ital Urol Androl. 2021. PMID: 33754613 Free article.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Expert Consensus on the Primary Aldosteronism Severity Classification and its strategic application in indicating adrenal venous sampling.
Murakami M, Naruse M, Kobayashi H, Parasiliti-Caprino M, Bioletto F, Brüdgam D, Stüfchen I, Reincke M, St-Jean M, Kraljevic I, Kastelan D, Nevalainen PI, Araujo-Castro M, Sukor N, Nijhoff MF, Matrozova J, Ragnarsson O, Shafigullina Z, Matikainen N, Markou A, Piaditis G, Izawa S, Katabami T, Ichijo T, Tanabe A, Tsuiki M, Kakutani M, Wada N, Masuda S, Bacca AV, Beuschlein F, Maiolino G, Falhammar H, Grytaas MA, Løvås K, Almeida MQ, Furnica RM, Puar T, Kmieć P, Masi S, Bourdeau I, Amar L, Dennedy MC, Fallo F, Deinum J, O'Toole S, Yamada T, Quinkler M, Lacroix A, Kocjan T. Murakami M, et al. Among authors: piaditis g. Eur J Endocrinol. 2025 Jun 30;193(1):85-96. doi: 10.1093/ejendo/lvaf117. Eur J Endocrinol. 2025. PMID: 40485198
Unravelling the Genetic Basis of Primary Aldosteronism.
Mourtzi N, Sertedaki A, Markou A, Piaditis GP, Charmandari E. Mourtzi N, et al. Among authors: piaditis gp. Nutrients. 2021 Mar 8;13(3):875. doi: 10.3390/nu13030875. Nutrients. 2021. PMID: 33800142 Free PMC article. Review.
Vitamin D and aspects of female fertility.
Voulgaris N, Papanastasiou L, Piaditis G, Angelousi A, Kaltsas G, Mastorakos G, Kassi E. Voulgaris N, et al. Among authors: piaditis g. Hormones (Athens). 2017 Jan;16(1):5-21. doi: 10.14310/horm.2002.1715. Hormones (Athens). 2017. PMID: 28500824 Free article. Review.
104 results